Massachusetts General Hospital
Boston, MA
Filters
Save & Share
Clear Filters
Diagnosis
Risk Level
If known, please select your risk level (IPSS-R / IPSS-M).
MDS Centers of Excellence
Accepting patients
MBG453
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
Learn more- Monoclonal Antibody
- TIM-3
- Phase 2
Accepting patients
Orca-T
A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
Learn more- Allogeneic Stem Cell Transplant
- T Cell (Allogeneic)
- Phase 3
- Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
A Controlled Multi-Arm Ph1 Study Evaluating the Safety and Feasibility of TCR Engineered Donor TCells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Haploidentical Allogeneic Stem Cell Transplantation
Learn more- T Cell (Allogeneic)
- Phase 1
- Has results
Accepting patients
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Learn more- JAK2 Inhibitor
- Maintenance
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
Accepting patients
Decitabine/Cedazuridine as Maintenance Therapy
A Phase Ib Study of Oral Decitabine/Cedazuridine as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Patients With Myeloid Neoplasms
Learn more- Cytidine Deaminase Inhibitor
- Hypomethylating Agents (HMA)
- Phase 1
Accepting patients
AZD6738
A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Learn more- Kinase Inhibitor
- Phase 1
Accepting patients
CC-91633 (BMS-986397)
A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Learn more- CELMoD
- Phase 1
Accepting patients
CLN-049
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Learn more- FLT3
- Tyrosine Kinase (TK) Inhibitor
- Phase 1
Accepting patients
LYT-200
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Learn more- Monoclonal Antibody
- Galectin-9 Protein
- Phase 1
Accepting patients
Bone Marrow & Kidney Transplant
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Learn more- Allogeneic Stem Cell Transplant
- Phase 2
Filters
Save & Share
Diagnosis
Risk Level
If known, please select your risk level (IPSS-R / IPSS-M).
MDS Centers of Excellence
Advanced Filters
Hide Trials
These are additional options that allow you to hide (or filter out) trial options that may not be right for you.
Trial Enrollment Status
Treatment Classifications
Filter results based on treatment classifications/type.
Trial Type
Phase
MDS Classification
Has your MDS been classified as primary (cause unknown) or secondary (treatment related)?